Current Status of the Diagnosis and Management of Osteoporosis
Open accessThe DOI matches its Crossref record; 229 of the 229 references it cites were found in a registry or an index.
Abstract
Osteoporosis has been defined as the silent disease of the 21st century, becoming a public health risk due to its severity, chronicity and progression and affecting mainly postmenopausal women and older adults. Osteoporosis is characterized by an imbalance between bone resorption and bone production. It is diagnosed through different methods such as bone densitometry and dual X-rays. The treatment of this pathology focuses on different aspects. On the one hand, pharmacological treatments are characterized by the use of anti-resorptive drugs, as well as emerging regenerative medicine treatments such as cell therapies and the use of bioactive hydrogels. On the other hand, non-pharmacological treatments are associated with lifestyle habits that should be incorporated, such as physical activity, diet and the cessation of harmful habits such as a high consumption of alcohol or smoking. This review seeks to provide an overview of the theoretical basis in relation to bone biology, the existing methods for diagnosis and the treatments of osteoporosis, including the development of new strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus, it is thought that imbalances in these molecular and cellular processes alter bone homeostasis, driving the pathophysiology of osteoporosis [5,6].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to bone densitometry, general blood and urine tests can provide important information about an individual’s overall health and any underlying conditions that may be contributing to osteoporosis.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This classification is widely accepted as a diagnostic criterion, with sensitivity and specificity close to 90% [6].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 1×
“The primary purpose of a pharmacological treatment is to reduce the risk of fractures and to improve the quality of life of people with osteoporosis [90].”
BackgroundEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Hernlund, E., Svedbom, A., Ivergård, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E. V., Jönsson, B., & Kanis, J. A. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0136-1 · Cited by 2,675 · cited 6×
“In 1993, the WHO defined osteoporosis as a systemic skeletal disease characterized by low bone mass, the deterioration of the microarchitecture of bone tissue, a consequent increase in bone fragility and a susceptibility to fractures [1].”
MethodInfluentialCompston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
An overview and management of osteoporosis
Sözen, T., Özışık, L., & Çalık Başaran, N. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2016.048 · Cited by 2,262 · cited 3×
“Individuals with uncomplicated osteoporosis may remain asymptomatic until a fracture occurs [5].”
BackgroundDiagnosis of osteoporosis and assessment of fracture risk
Kanis, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,260 · cited 1×
“5–2; and (v) severe osteoporosis value: the risk is similar to that of established osteoporosis [89].”
BackgroundStroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952 · cited 1×
“It is another clear cause of bone density loss, not only because of the drop in hormone levels but also because, histologically, there is a decrease in the average thickness of the bone wall, but bone resorption remains high with aging [34].”
BackgroundEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900 · cited 1×
“race, since Caucasians and Asians are at a greater risk than Blacks and Polynesians [32]; sex, since it has been found that the risk is greater in women than in men [33]; and age, since each decade increases the risk by 1.”
BackgroundHorwitz, E. M., Prockop, D. J., Fitzpatrick, L. A., Koo, W. W. K., Gordon, P. L., Neel, M., Sussman, M., Orchard, P., Marx, J. C., Pyeritz, R. E., et al. (1999) · Nature Medicine · doi:10.1038/6529 · Cited by 1,824 · cited 1×
“Decades ago, clinical studies were already conducted in children, using bone marrow MSCs (BM-MSCs) for the treatment of severe osteogenesis imperfecta [140].”
Background
Research works printed but not linked: 2
- 31. Quevedo L.I. Martínez B.M. Castillo N.M. Rivera F.N. [Vitamin D receptor gene polymorphisms and risk of hip fracture in Chilean elderly women] Rev. Med. Chile 2008 136 475 481 18769790
- 107. Società Italiana Dell’osteoporosi del Metabolismo Minerale e delle Malattie dello Scheletro Clinical Cases in Mineral and Bone Metabolism: The Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases CIC Edizioni Internazionali Rome, Italy 2004
Cited by
Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics
Adejuyigbe, B., Kallini, J., Chiou, D., & Kallini, J. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914583 · Cited by 148
“Local molecules such as TGF-β play a pivotal role in attracting and preparing osteoblasts to initiate bone formation [4,6,7].”
InfluentialHsu, S.-H., Chen, L.-R., & Chen, K.-H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212139 · Cited by 118
“Although this condition affects both men and women, it predominantly occurs in women aged 51 to 75, who are characterized by accelerated bone loss during this period [14].”
Cellular senescence in skeletal disease: mechanisms and treatment
He, X., Hu, W., Zhang, Y., Chen, M., Ding, Y., Yang, H., He, F., Gu, Q., & Shi, Q. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00501-5 · Cited by 109
“Unfortunately, although various drugs, (such as bisphosphonates, recombinant human parathyroid hormone, denosumab for OP, and paracetamol for OA), have been licenced, their benefits are limited due to side effects or the poor overall health of elderly individuals (2, 3).”
BackgroundThe emerging role of Piezo1 in the musculoskeletal system and disease
Lei, L., Wen, Z., Cao, M., Zhang, H., Ling, S. K.-K., Fu, S., Qin, L., Xu, J., & Yung, P. S. (2024) · Theranostics · doi:10.7150/thno.96959 · Cited by 86
“In clinical scenarios, appropriate physical activity is beneficial for patients with musculoskeletal disorders, including OP [161], OA [162], muscle atrophy [163], IDD [164], and tendinopathy [165].”
BackgroundFeng, R., Wang, Q. K., Yu, T., Hu, H., Wu, G., Duan, X., Jiang, R., Xu, Y., & Huang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112341 · Cited by 74
Saurav, S., Sharma, P., Kumar, A., Tabassum, Z., Girdhar, M., Mamidi, N., & Mohan, A. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46010038 · Cited by 66
“One of main causes of impairment worldwide is bone loss brought on by non-healing fractures following trauma, diseases like osteoporosis and tumors, which impact millions of individuals’ worldwide [2].”
BackgroundInfluentialA pooled analysis of the association between sarcopenia and osteoporosis
Yu, X., Sun, S., Zhang, S., Hao, Q., Zhu, B., Teng, Y., Long, Q., Li, S., Lv, Y., Yue, Q., et al. (2022) · Medicine · doi:10.1097/md.0000000000031692 · Cited by 68
“Osteoporosis is a systemic condition of the skeleton that is characterized by low bone mass and quality, which can increase the susceptibility to sarcopenia.[1,2] Osteoporosis is related to an increased risk of sarcopenia.”
BackgroundPrevalence and Risk Factors of Osteoporosis: A Cross-Sectional Study in a Tertiary Center
Özmen, S., Kurt, S., Timur, H. T., Yavuz, O., Kula, H., Demir, A. Y., & Balcı, A. (2024) · Medicina · doi:10.3390/medicina60122109 · Cited by 70
“Osteoporosis is a severe and progressive disease that remains silent until symptoms appear and stands out as the most common metabolic bone disease [2].”
InfluentialThe role of magnesium in the pathogenesis of osteoporosis
Liu, L., Luo, P., Wen, P., & Xu, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1406248 · Cited by 70
The Role of Cortisol and Dehydroepiandrosterone in Obesity, Pain, and Aging
Erceg, N., Mićić, M., Forouzan, E., & Knežević, N. N. (2025) · Diseases · doi:10.3390/diseases13020042 · Cited by 49
“Different factors have an effect on bone formation and reabsorption, including sex, age, genetics, nutrients, physical activity, BMI, drugs, lifestyle, and chronic medical conditions [132].”
The role of calcium channels in osteoporosis and their therapeutic potential
Hao, Y., Yang, N., Sun, M., Yang, S., & Chen, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1450328 · Cited by 43
Niwczyk, O., Grymowicz, M., Szczęsnowicz, A., Hajbos, M., Kostrzak, A., Budzik, M. P., Maciejewska-Jeske, M., Bala, G., Smolarczyk, R., & Męczekalski, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076840 · Cited by 49
Dong, Q. Z., Ren, G., Li, Y., & Hao, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-57796-3 · Cited by 44
Evaluation of the information quality related to osteoporosis on TikTok
Li, A., Xing, Q., Zhang, Y., Zhan, W., Zhu, S., Lou, L., Jiang, C., Guo, Z., & Sun, H. S. (2024) · BMC Public Health · doi:10.1186/s12889-024-20375-2 · Cited by 37
“…includes idiopathic osteoporosis and degenerative osteoporosis with unknown pathogenesis, while secondary osteoporosis accounts for less than 5% of all osteoporosis cases, mainly due to disease and drug use, such as diabetes induced-osteoporosis and glucocorticoid-dependent osteoporosis [3, 4].”
BackgroundHuo, R., Wei, C., Huang, X., Yang, Y., Huo, X., Meng, D., Huang, R., Huang, Y., Xia Shuang, Z. H. U., Yang, Y., et al. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-05068-1 · Cited by 32
“It is a serious, chronic, progressive, and clinically asymptomatic condition, and it is the most common metabolic bone disease [2].”
BackgroundAssociation between hypertension and osteoporosis: a population-based cross-sectional study
Huang, Y., & Ye, J. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07553-4 · Cited by 34
“…develop corresponding prevention strategies Osteoporosis is a metabolic degenerative bone disease characterised by decreased bone mass, increased bone fragility, structural deterioration of bone tissue, and a high prevalence of fracture and is assessed in clinical practice mainly by BMD [1, 3].”
BackgroundPatel, D., & Saxena, B. (2024) · Journal of Orthopaedic Reports · doi:10.1016/j.jorep.2024.100472 · Cited by 33
Prevalence rate of primary osteoporosis in China: a meta-analysis
Lyu, F. F., Ramoo, V., Chui, P. L., Ng, C. G., & Zhang, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-18932-w · Cited by 31
Wei, J., Liu, Q., Yuen, H.-Y., Lam, A. C.-H., Jiang, Y., Yang, Y., Liu, Y., Zhao, X., & Xiao, L. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.11.003 · Cited by 38
“It is mainly recognized as a possible consequence of aging and affects postmenopausal women and elderly individuals [1].”
Osteoporosis and depression in perimenopausal women: From clinical association to genetic causality
Guo, X., She, Y., Liu, Q., Qin, J., Wang, L., Ai-li, X., Qi, B., Sun, C., Xie, Y., Ma, Y., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.019 · Cited by 28
A review of mathematical modeling of bone remodeling from a systems biology perspective
Cook, C. V., Lighty, A. M., Smith, B. J., & Ford Versypt, A. N. (2024) · Frontiers in Systems Biology · doi:10.3389/fsysb.2024.1368555 · Cited by 25
Bridging the Gap: Pregnancy—And Lactation—Associated Osteoporosis
Carşote, M., Turturea, M. R., Valea, A., Buescu, C., Nistor, C., & Turturea, I. F. (2023) · Diagnostics · doi:10.3390/diagnostics13091615 · Cited by 25
“Moreover, half of the women were smokers, smoking being a traditional risk factor for bone loss and increased fracture risk at any age [38,94,95].”
BackgroundOsteoporosis: Spotlight on current approaches to pharmacological treatment
Sindel, D. (2023) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2023.13054 · Cited by 26
“Bisphosphonates are the most commonly used first-line drugs with proven efficacy to reduce the risk of vertebral, hip, and non-vertebral fractures.[16,17,38-42] They target the osteoclasts binding to inorganic compounds of the bone, thereby inducing osteoclast apoptosis and inhibiting bone turnover and resorption.”
The role and mechanism of RNA-binding proteins in bone metabolism and osteoporosis
Wu, J., Niu, L., Yang, K., Xu, J., Zhang, D., Ling, J., Xia, P., Wu, Y., Liu, X., Liu, J., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102234 · Cited by 24
Revolutionizing bone healing: the role of 3D models
Pace, R. D., Iaquinta, M. R., Benkhalqui, A., D’Agostino, A., Trevisiol, L., Nocini, R., Mazziotta, C., Rotondo, J. C., Bononi, I., Tognon, M. G., et al. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00225-1 · Cited by 22
“Osteoblast proliferation is reduced in older adults, postmenopausal women, and in specific bones sites like the femoral head (Aibar-Almazán et al. 2022).”
The potential therapeutic effects of Panax notoginseng in osteoporosis: A comprehensive review
Zhu, Z., Bai, Z., Cui, Y., Li, X., & Zhu, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156703 · Cited by 21
Chitosan nanovectors for siRNA delivery: New horizons for nonviral gene therapy
Rahimi, M., Kariminezhad, Z., Rondon, E.-P., Fahmi, H., Fernandes, J., & Benderdour, M. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.123581 · Cited by 23
Khiyali, Z., Rashedi, V., Tavacol, Z., Dehghan, A., & Bijani, M. (2024) · BMC Geriatrics · doi:10.1186/s12877-024-04678-y · Cited by 21
“…bone disease, osteoporosis is caused by a lack of balance in the function of bone cells (imbalance between deterioration and production of bone), leading to a reduction in bone density and atrophy in bone tissues, which in turn increases the brittleness of bones and the risk of fractures [7].”
BackgroundResultLi, Q., Wang, J., & Zhao, C. (2024) · Biomedicines · doi:10.3390/biomedicines12102389 · Cited by 24
“This condition, often termed the “silent disease” due to its asymptomatic nature until a fracture occurs, represents a significant public health concern worldwide [1,2].”
BackgroundSkała, E., & Szopa, A. (2023) · Molecules · doi:10.3390/molecules28093754 · Cited by 22
“Osteoporosis can usually occur with aging and after menopause due to estrogen deficiency, which contributes to the reduction of bone density and bone mass and degradation of the microstructure [129].”
BackgroundLiu, X., Xu, H.-W., Yi, Y., Zhang, S., Chang, S.-J., Pan, W., & Wang, S. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167273 · Cited by 24
Tarighatnia, A., Amanzadeh, M., Hamedan, M., Mohammadnia, A., & Nader, N. D. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-01626-z · Cited by 23
“However, DEXA can present challenges for patients with metal implants, incomplete or inaccurate health information, or those who cannot fully cooperate during the imaging process [8].”
Posttranslational Modification in Bone Homeostasis and Osteoporosis
Lin, Y., Jiang, S., Yao, Y., Li, H., Jin, H., Yang, G., Ji, B., & Li, Y. (2025) · MedComm · doi:10.1002/mco2.70159 · Cited by 26
“Primary OP accounts for over 95%, which mainly covers involutional and idiopathic OP that have an influence usually on the young and the senior respectively [25].”
Cao, Z., Niu, X., Wang, M., Yu, S., Wang, M., Mu, S., Liu, C., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115454 · Cited by 19
BMP9 alleviates iron accumulation-induced osteoporosis via the USP10/FOXO1/GPX4 axis
Huang, Y., Zhang, J., Zhu, Y., Zhao, R., Zhou, X., Qu, X., Duan, Y., Li, N., Tang, D., & Luo, X. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.012 · Cited by 27
“This condition is particularly prevalent among the elderly, especially women, and has emerged as a significant global public health issue [2,3].”
Effects of resveratrol in an animal model of osteoporosis: a meta-analysis of preclinical evidence
Zhao, J., Zhou, G., Yang, J., Pan, J., Sha, B., Luo, M., Yang, W., Liu, J., & Zeng, L. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1234756 · Cited by 17
“The following data were extracted: (1) basic information of the included study: author, title, year of publication, animal species, weight, age, and sample size, (2) specific details of intervention measures, including medication dosage and duration, (3) the various information elements of bias risk assessment, and (4…”
BackgroundMethodEk, S., Meyer, A. C., Sääf, M., Hedström, M., & Modig, K. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01312-z · Cited by 17
“Such pharmacological secondary fracture prevention has proven to be effective in slowing bone loss and decreasing the risk of new fractures [7].”
BackgroundLiu, S., Tan, Y., Huang, W., Luo, H., Pan, B., & Wu, S. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152304 · Cited by 18
Su, Y., Yu, G., Li, D., Lu, Y. W., Ren, C., Xu, Y., Yang, Y., Zhang, K., Ma, T., & Zhong, L. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2023.1289976 · Cited by 18
Qi, J.-L., Zhang, Z., Zhou, D., Shan, T., & Yin, Z. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04671-6 · Cited by 17
“Osteoporosis (OP) is an age-related bone disease in which decreased bone density and bone strength are the main features of patients with OP [1].”
BackgroundLin, X., Shen, R., Zheng, X., Shi, S., Dai, Z., & Fang, K. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07903-2 · Cited by 17
“Osteoporosis is a silent disease characterized by low bone mass and structural deterioration, leading to an increased risk of fractures [1].”
BackgroundTraumatic rib fracture patterns associated with bone mineral density statuses derived from CT images
Tang, Y., Hong, W., Xu, X.-X., Li, M., & Jin, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1304219 · Cited by 15
ZIP transporters‐regulated Zn 2+ homeostasis: A novel determinant of human diseases
Liu, H., Li, L., & Lu, R. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31223 · Cited by 18
Yan, K., Zhang, R., Wang, J., Chen, H., Zhang, Y., Cheng, F., Jiang, Y., Min, W., Wu, Z., Chen, X., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2449225 · Cited by 16
Application and Prospect of Metabolomics in the Early Diagnosis of Osteoporosis: A Narrative Review
Li, Y., Si, Y., Ma, Y., & Yin, H. (2023) · Bioanalysis · doi:10.4155/bio-2023-0131 · Cited by 16
Duan, J.-Y., You, R., Zhou, Y., Xu, F., Lin, X., Shan, S., Zheng, M., Lei, L.-M., Li, F., Guo, B., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae060 · Cited by 14
Weiss, M. B., Syed, S. A., Whiteson, H. Z., Hirani, R., Etienne, M., & Tiwari, R. K. (2024) · Life · doi:10.3390/life14050561 · Cited by 15
He, Q., Chen, B., Liang, F., & Zhang, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1363889 · Cited by 15
“An estimated 1.5 million fractures are caused by OP each year in the United States (3, 4).”
BackgroundInfluentialZhang, S., Wu, S., Xia, B., He, Q., Mi, N., Zhao, J., Hu, L., Wang, D., Zheng, L., Sheng, P., et al. (2024) · Bone · doi:10.1016/j.bone.2024.117135 · Cited by 14
Pan, Y., Wu, Y.-B., Wang, H., Yu, T.-H., He, D., Lu, X.-J., Zhao, F., Ma, H.-F., Wang, Y., & Cai, Y.-K. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-59 · Cited by 14
“Osteoporosis has been defined as a silent epidemic becoming a public health risk due to its severity, chronicity, progression, and that it affects mainly senile people (3).”
Zhao, Z., Deng, Y., Li, L., Zhū, L., Wang, X., Sun, H., Li, X., Han, X., & Li, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06426-1 · Cited by 16
“Based on well-established imaging techniques, identified pathologies, and blood markers of bone metabolism [31, 32].”
Targeting Cellular Senescence: Pathophysiology in Multisystem Age-Related Diseases
Liu, J., Yu, H., & Xu, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13071727 · Cited by 15
“…to side effects or the physical condition of older adult patients, shifting research focus to cellular senescence—as a common pathological basis for age-related skeletal diseases, its mediated inflammatory microenvironment and matrix degradation offer a new rationale for targeted therapy [143,144].”
Kang, J., Wu, X., Li, Y., Zhao, S., Wang, S., & Yu, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425610 · Cited by 14
“The prevalence of OP is steadily increasing due to changing global demographics, earning it the moniker ‘ the silent disease of the 21st century ’ (4).”
Zhu, G., Guo, B., & Liang, J. (2024) · Bone · doi:10.1016/j.bone.2024.117255 · Cited by 15
Mohammadi-Sadr, M., Cheki, M., Moslehi, M., Zarasvandnia, M., & Salamat, M. R. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.10.049 · Cited by 13
Tang, L., Fan, X., Xu, Y., Yeming, Z., & Li, G. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70071 · Cited by 15
Miao, T., Li, X., Zhang, W.-H., Yang, F.-Y., & Wang, X. (2025) · PeerJ · doi:10.7717/peerj.19616 · Cited by 10
Liang, X., Shi, W., Zhang, X., Pang, R., Zhang, K., Xu, Q., Xu, C., Wan, X. H., Cui, W., Li, D., et al. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01708-3 · Cited by 17
“…treatment of OP have limitations, and patients with osteoporosis have poor compliance with pharmacological treatment due to adverse reactions associated with drug side effects, so it is crucial to find other risk factors for OP to optimize the diagnosis, prevention, and treatment of OP [8–11].”
BackgroundPan, K., Lu, Y., Cao, D., Peng, J., Zhang, Y., & Li, X. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10564-w · Cited by 12
Wei, Q., Ouyang, M., Guo, X., Fu, X., Liu, T., Luo, Y., Tang, H., Yang, Y. S., Gao, X., & Mao, H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176666 · Cited by 14
Yalaev, B. I., Tyurin, A. V., Akhiiarova, K. E., & Khusainova, R. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137312 · Cited by 12
“Currently, osteoporosis diagnosis is based on bone mass assessment using dual-energy X-ray absorptiometry (DEXA) and fracture risk calculation using online calculators such as FRAX [6].”
MethodBojtor, B., Balla, B., Vaszilkó, M., Szentpéteri, S., Putz, Z., Kosa, J. P., & Lakatos, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910488 · Cited by 14
“Antiresorptive agents such as BPs (e.g., zoledronic acid, alendronate, ibandronate, risedronate) and denosumab are primarily used to treat osteoporosis, the most common metabolic bone disease [20].”
BackgroundPatel, P., Trivedi, A., Prajapati, B. G., & Kapoor, D. U. (2025) · Next research. · doi:10.1016/j.nexres.2025.100142 · Cited by 12
ACT001 improves OVX-induced osteoporosis by suppressing the NF-κB/NLRP3 signaling pathway
Li, Y., Yang, J., Lin, M.-L., Liu, T., Lu, W., Yang, Y., Liu, Z., Li, J.-H., Zhang, G., & Guo, J. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01189-3 · Cited by 16
“Osteoporosis is a common chronic metabolic bone disease affecting bone health and overall quality of life in older adults, and it is known as “the silent killer of the 21st century” and becomes a major public health concern worldwide (Aibar-Almazan et al. 2022).”
Wang, J., Hou, H., Li, Y., Tang, W., Gao, D., Liu, Z., Gao, X., Zhao, F., Feng, S., Tan, H., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23531 · Cited by 17
“Osteoporosis is often described as a silent disease with no apparent clinical signs in its early stages [5].”
BackgroundCai, Y., Sun, H., Song, X., Zhao, J., Xu, D., & Liu, M. (2023) · Aging · doi:10.18632/aging.205136 · Cited by 14
“Osteoporosis is the most common skeletal disease in the world, with up to millions of fragility fractures caused by osteoporosis each year worldwide, and the root cause of the disease is the imbalance in bone turnover in the body [28].”
Priya, P. S., Surisetti, R., Gopi, S., Pachaiappan, R., Pasupuleti, M., Rajagopal, R., Alfarhan, A., Guru, A., & Arockiaraj, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135662 · Cited by 12
Lan, Z., Liu, C., Wang, H., Wang, Y., Kan, S., Jiao, Y., & Yi-bin, D. (2025) · Archives of Public Health · doi:10.1186/s13690-025-01500-y · Cited by 12
“Concurrently, the use of bisphosphonates, bone-forming drugs (such as denosumab and teriparatide) and novel regenerative medicine treatments such as cell therapies and bioactive hydrogels, has been demonstrated to be efficacious in the treatment of osteoporosis [30, 31].”
Mahdi, M. Y., Husam, K., & Majeed, M. A. (2025) · Лабораторная диагностика Восточная Европа · doi:10.34883/pi.2025.14.1.024
Mortality following fragility hip fracture in China: a record linkage study
Hua, Y., Li, Y., Zhou, J., Fan, L., Huang, F., Wu, Z., Xue, H., Yang, B., Chen, P., Rui, Y., et al. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01304-z · Cited by 11
“We found fragility fractures in the Chinese population were associated with high mortality, similar to findings from previous studies in other Asian populations [7, 19–23].”
Shen, J., Li, Y., Li, J., Shen, M., Xu, Y., Zhang, Y., Yang, X., Wang, C., Gou, Z., Xu, S., et al. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.113054 · Cited by 11
Photobiomodulation Dose–Response on Adipose-Derived Stem Cell Osteogenesis in 3D Cultures
Silva, D. D., Crous, A., & Abrahamse, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179176 · Cited by 12
Nrf2 signaling pathway: focus on oxidative stress in osteoporosis
Gu, H.-Y., Liu, N., Lin, F.-X., & Yin, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07592-0 · Cited by 10
Yuan, X., Liang, Y., Yang, H. J., Feng, L., Sun, H., Li, C., & Qin, J. (2023) · Academic Radiology · doi:10.1016/j.acra.2023.10.035 · Cited by 10
Pharmacology and mechanisms of apigenin in preventing osteoporosis
Sun, L. N., Wang, Y., Jiazhe, D., Xilin, X., & Zhang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1486646 · Cited by 11
The relationship between non-HDL-C/HDL-C ratio and bone mineral density: an NHANES study
Qi, S., Peng, B., Xu, Z., Qiu, D., & Tan, G. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1486370 · Cited by 13
The association between dietary omega-3 intake and osteoporosis: a NHANES cross-sectional study
Liu, Z., Cai, S., Chen, Y., Peng, Z., Jian, H., Zhang, Z., & Huang, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1467559 · Cited by 12
Key genes linking gut microbiota, immune cells, and osteoporosis: A multi-omics approach
Li, Q., Guo, R., Wu, Z., Zhao, C., & Shen, C. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107412 · Cited by 10
Predictive efficacy of different diagnostic criteria for sarcopenia in osteoporosis and fractures
Zhan, Z., Zhang, Y., Wu, J., Lin, J., & Yan, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-93988-1 · Cited by 10
Mitochondrial Transplantation: A Paradigm Shift in Osteoporosis Therapy
Shen, J., Lai, Y., Peng, Q., Lin, X., Chen, S., Guo, L., Xu, M., Lu, Y., Zhu, J., Lin, X., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s537166 · Cited by 12
Zhou, P., Lü, K., Li, C., Xu, M.-Z., Ye, Y.-W., Shan, H.-Q., & Yin, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1404152 · Cited by 11
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction
Duong, H., Kafer, G. R., & Maugham, M. (2024) · Endocrine Related Cancer · doi:10.1530/erc-24-0294 · Cited by 17
The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review
Mercurio, M., Spina, G., Galasso, O., Gasparini, G., Segura‐Garcìa, C., Fazio, P. D., & de Filippis, R. (2024) · Diagnostics · doi:10.3390/diagnostics14232745 · Cited by 10
“Often referred to as a “silent disease”, osteoporosis is typically only identified after a fracture occurs [12].”
Song, Y., Zhang, F., Jia, G., Fan, Y., Zeng, H., Sun, M., Qian, J., Qi, S., Chen, Z., Jin, X., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.004 · Cited by 10
Wang, J., Wang, Y., Ren, J., Li, Z., Guo, L., & Lv, J. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf105 · Cited by 12
Liu, S., Sun, Y., Man, Y.-N., He, M., & Huang, P. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06424-5 · Cited by 9
Lin, Y., Wang, X., Wu, R., Zhou, J., & Feng, F. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01506-z · Cited by 11
“Both conditions have been linked to sub-optimal dietary patterns, excessive calorie intake, and insufficient physical activity [54, 55].”
BackgroundExploring epigenetic strategies for the treatment of osteoporosis
Yi, S.-J., Lim, J., & Kim, K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09353-4 · Cited by 9
“These pharmacological interventions, when combined with lifestyle adjustments, exercise, and dietary supplements, are instrumental in effectively managing osteoporosis [16].”
PMAIP1 regulates autophagy in osteoblasts via the AMPK/mTOR pathway in osteoporosis
Gao, Y., Huang, A., Zhao, Y., & Du, Y. (2024) · Human Cell · doi:10.1007/s13577-024-01067-w · Cited by 10
“Osteoporosis (OP) is a common skeletal metabolic disease characterized by the loss of bone mass and deterioration of bone tissue microarchitecture, which can lead to brittle fracture [1, 2].”
Oral and Gingival Crevicular Fluid Biomarkers for Jawbone Turnover Diseases: A Scoping Review
Fadli, N. A., Rahman, M. A., Karsani, S. A., & Ramli, R. (2024) · Diagnostics · doi:10.3390/diagnostics14192184 · Cited by 10
Chaudhary, N. K., Sunuwar, D. R., Sapkota, M. R., Pant, S., Pradhan, M., & Bhandari, K. K. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00591-7 · Cited by 9
“Osteoporosis, known as a silent disease in the 21st century [1], is a major public health concern worldwide [2, 3] because it generally does not manifest until an osteoporotic fracture occurs [4].”
BackgroundTan, C., Cong, S., Xie, Y., & Zhi, Y.-J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083650 · Cited by 9
“First-line pharmacological agents include antiresorptive drugs, such as bisphosphonates (e.g., alendronate and zoledronate), which suppress osteoclast activity by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway [7,8].”
AnnexinA6: a potential therapeutic target gene for extracellular matrix mineralization
Yang, J., Pei, T., Su, G., Duan, P., & Liu, X. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1201200 · Cited by 8
Wang, H. Z., Shan, K., Li, Y., Wu, S., Zhou, C., Shan, T., Wang, M., Kang, X.-C., Zhou, L., Lyu, Z., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423555 · Cited by 11
Wang, L., Guo, X., Qin, J., Jin, Z., Liu, Q., Sun, C., Sun, K., Li, L., Wei, X., & Zhang, Y. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07225-y · Cited by 8
Zhou, P., Liu, L., Lü, K., Xu, M.-Z., Ye, Y.-W., Li, C., & Yin, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-78926-x · Cited by 8
Feng, L.-L., Lü, K., Li, C., Xu, M.-Z., Ye, Y.-W., Yin, Y., & Shan, H.-Q. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-08276-w · Cited by 8
“An imbalance between bone resorption and bone formation is one of essential characteristics of osteoporosis [24], which is affecting a huge number of individuals in China [25].”
Lei, Y., Zhang, R., Li, Y., Pang, H., Fu, Q., Chen, C., & Liu, F. (2025) · Phytotherapy Research · doi:10.1002/ptr.8464 · Cited by 17
“Furthermore, osteoporosis, the most prevalent metabolic bone disorder, represents a significant global public health concern (Aibar-Almazán et al. 2022).”
Zhou, Z., Huo, S., & Li, Z. (2024) · Coatings · doi:10.3390/coatings14010097 · Cited by 9
Zhao, H., Wang, J., Zheng, Y., Liu, Z., Jiang, Y., Suo, C., Chen, X., & Xu, K. (2025) · Bone · doi:10.1016/j.bone.2025.117521 · Cited by 7
Metadata
- Authors
- Aibar-Almazán, A., Voltes-Martínez, A., Castellote-Caballero, Y., Afanador-Restrepo, D. F., Carcelén-Fraile, M. D. C., & López-Ruiz, E.
- Affiliations
- Department of Health Sciences, Campus de Las Lagunillas SN, University of Jaén, E-23071 Jaén, Spain
- Universidad de Granada (ES)
- Fundación Universitaria del Área Andina (CO)
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-21
- Volume
- 23
- Issue
- 16
- Pages
- 9465
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9408932
- OpenAlex
- W4293030541
- Cited by
- 412
- References
- 229
- Citations by year
- 2026: 79 · 2025: 156 · 2024: 128 · 2023: 43 · 2022: 6
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- 2014–2020 Operational Programme FEDER in Andalusia (FMM-AP17196-2019)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteoporosis diagnosis, bone densitometry, dual-energy X-ray absorptiometry, anti-resorptive drugs, regenerative medicine, cell therapy, bioactive hydrogels, non-pharmacological treatment, physical activity, diet, smoking, alcohol consumption, bone resorption, bone biology, postmenopausal women, older adults
- MeSH terms
- Aged, Bone Resorption, Female, Humans, Osteoporosis, Smoking, Health Behavior, Exercise, Bone Density, Osteoporosis, Postmenopausal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.